Fifth Third Bancorp’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Fifth Third Bancorp’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,461	Closed	-$644K	–	2563
2021 Q1	$644K	Hold	6,461	–	–	﹤0.01%	635
2020 Q4	$799K	Hold	6,461	–	–	﹤0.01%	593
2020 Q3	$629K	Hold	6,461	–	–	﹤0.01%	603
2020 Q2	$1.01M	Hold	6,461	–	–	0.01%	506
2020 Q1	$933K	Hold	6,461	–	–	0.01%	487
2019 Q4	$1.32M	Hold	6,461	–	–	0.01%	480
2019 Q3	$519K	Hold	6,461	–	–	﹤0.01%	632
2019 Q2	$610K	Hold	6,461	–	–	﹤0.01%	590
2019 Q1	$552K	Hold	6,461	–	–	﹤0.01%	592
2018 Q4	$362K	Hold	6,461	–	–	﹤0.01%	702
2018 Q3	$528K	Hold	6,461	–	–	﹤0.01%	677
2018 Q2	$226K	Sell	6,461 -6,000	-48%	-$183K	﹤0.01%	862
2018 Q1	$256K	Hold	12,461	–	–	﹤0.01%	823
2017 Q4	$353K	Hold	12,461	–	–	﹤0.01%	740
2017 Q3	$388K	Hold	12,461	–	–	﹤0.01%	727
2017 Q2	$394K	Sell	12,461 -5,000	-29%	-$123K	﹤0.01%	748
2017 Q1	$395K	Buy	+17,461	New	+$431K	﹤0.01%	751

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fifth Third Bancorp's RETA Position: Q2 2021 in Review

Fifth Third Bancorp sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2021, closing a stake of 6,461 shares — an estimated $644K sold.

Fifth Third Bancorp first reported a position in RETA in Q1 2017 and held it in 17 quarters. The position peaked at $1.32M in Q4 2019. 194 funds tracked by Wall St. Rank hold RETA as of Q2 2021.

Fifth Third Bancorp reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2021 after selling out during the quarter.
Fifth Third Bancorp sold 6,461 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2021, an estimated $644K.
Fifth Third Bancorp first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 17 quarters.
Fifth Third Bancorp's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.32M in Q4 2019.
194 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2021.

Based on Fifth Third Bancorp's 13F filing for Q2 2021, filed 6 Aug 2021.